Streetbeat News

Analyst Ratings

YMAB

In the last quarter, Y-mAbs Therapeutics (NASDAQ:YMAB) received 3 bullish ratings and 1 somewhat bearish rating from analysts. The company's average 12-month price target is $14.75, an increase of 5.36% from the previous average of $14.00.

Portfolio Pulse from Benzinga Insights

August 14, 2023 | 1:00 pm

BBIO

BridgeBio Pharma (NASDAQ:BBIO) has received positive analyst ratings in the last quarter, with an average price target of $47.25, indicating an upside from the current price of $31.07. The average price target has increased by 43.18% over the past month.

Portfolio Pulse from Benzinga Insights

August 14, 2023 | 1:00 pm

WMT

Stifel analyst Mark Astrachan has maintained a 'Hold' rating on Walmart (NYSE:WMT) and raised the price target from $163 to $167.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 14, 2023 | 1:00 pm

BHG

Bright Health Gr (NYSE:BHG) has received 7 analyst ratings in the last quarter, with 1 bullish, 2 indifferent, and 4 somewhat bearish. The average 12-month price target for the company is $1891.71, a decrease of 13.08% from the previous average of $2176.50.

Portfolio Pulse from Benzinga Insights

August 14, 2023 | 1:00 pm

CARG

JP Morgan analyst Rajat Gupta maintains an Overweight rating on CarGurus (NASDAQ:CARG) but lowers the price target from $29 to $27.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 14, 2023 | 12:58 pm

PX

Morgan Stanley analyst Michael Cyprys has maintained an Overweight rating on P10 (NYSE:PX) and raised the price target from $13 to $14.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 12:58 pm

ANIX

Anixa Biosciences (NASDAQ:ANIX) announced that its Chief Development Officer, Dr. Pamela D. Garzone, will present at the 8th Annual CAR-TCR Summit. The presentation will focus on the development of CAR-T for ovarian cancer and other solid tumors, and will detail the ongoing clinical trial (NCT05316129) in collaboration with Moffitt Cancer Center. The trial is a Phase I clinical trial of autologous T cells genetically engineered to target the follicle-stimulating hormone receptor (FSHR) in patients with recurrent ovarian cancer.

Portfolio Pulse from Happy Mohamed

August 14, 2023 | 12:58 pm

BWXT

Truist Securities analyst Michael Ciarmoli maintains a 'Buy' rating on BWX Technologies and raises the price target from $77 to $83.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 14, 2023 | 12:58 pm

IONQ

Morgan Stanley analyst Scott Fessler maintains an Equal-Weight rating on IonQ (NYSE:IONQ) and raises the price target from $7 to $16.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 12:57 pm

HE

Hawaiian Electric's stock has been downgraded by Wells Fargo, which maintained an Underweight rating and lowered its price target from $35 to $25. This has led to a decrease in the trading price of Hawaiian Electric shares.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2023 | 12:56 pm